{"schema_version":"secwatch.filing_event.v1","accession":"0001437749-26-021833","form_type":"8-K","ticker":"VXRT","cik":"0000072444","company_name":"Vaxart, Inc.","filed_at":"2026-06-26T20:07:23+00:00","discovered_at":"2026-06-26T20:08:00.533445+00:00","generated_at":"2026-06-26T20:08:29.954680+00:00","sec_items":["1.01","8.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Vaxart: BARDA modifies COVID-19 trial award to ~$345M; releases $29M for data analysis","bullets":["Total BARDA funding reduced ~$116M to ~$345M after 50% participant reduction due to partial termination in Aug 2025.","Modification releases ~$29M for trial completion and exploratory safety/efficacy analyses.","Vaxart plans to report 12-month data from 400-participant sentinel cohort in coming weeks; main cohort (5,085) data in H1 2027.","CEO states modification is necessary step to unblinding and reporting first data set."],"urls":{"canonical":"https://secwatch.observer/filing/0001437749-26-021833","json":"https://secwatch.observer/filing/0001437749-26-021833.json","markdown":"https://secwatch.observer/filing/0001437749-26-021833.md","text":"https://secwatch.observer/filing/0001437749-26-021833.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/72444/000143774926021833/0001437749-26-021833-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/72444/000143774926021833/vxrt20260626_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-26T20:08:29.954680+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}